a collection of information unless it contains a valid OMB control number.

Application Number 10561880 Filing Date 2005-12-23 INFORMATION DISCLOSURE First Named Inventor Quiambao, Jr. STATEMENT BY APPLICANT Art Unit (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 733310/00001A

	U.S.PATENTS							
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva	Columns, nt Passag Appear	ines where es or Relevant
	1	3637046		1972-01-25	Emmons			
	2	3904161		1975-09-09	Scott			
	3	4871141		1989-10-03	Chen			
	4	5100198		1992-03-31	Baltzell			
	5	5255954		1993-10-26	Rogers			
	6	5323941		1994-06-28	Sobolev			
	7	5478041		1995-12-26	Mayne			
	8	5492430		1996-02-20	Jones			

	9	5518218		1996-05-21	Leonard		
	10	5641197		1997-06-24	Springmann		
	11	5749386		1998-05-12	Samuel, Jr.		
	12	5836327		1998-11-17	Davis		
	13	6439659	B1	2002-08-27	Neubauer, Jr.		
	14	6474097	B2	2002-11-05	Troppedi et al.		
	15	6536733	B1	2003-03-25	Sharp		
If you wish	h to a	dd additional U.S. Paten		<u>_</u>	ease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear
	1	20010035202	A1	2001-11-01	Moskowitz et al.		
If you wish to add additional U.S. Published Application citation information please click the Add button. Add							
	FOREIGN PATENT DOCUMENTS Remove						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10561880
Filing Date		2005-12-23
First Named Inventor Quian		nbao, Jr.
Art Unit		
Examiner Name		
Attorney Docket Numb	er	733310/00001A

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	EP0860113	EP	A1	1998-08-26	Chiu		
If you wish	h to a	dd additional Foreign	Patent Docum	ent citation	information p	lease click the Add butto	n Add	-
			NON-PA	TENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, sympostum, catabg, etc), date, pages(s), volume-issue numbor(s), publisher, city and/or country where published.				Тŝ			
	1							
If you wisl	h to a	dd additional non-pate	ent literature do	cument cit	ation informa	tion please click the Add	button Add	
				EXAMINE	R SIGNATUR	RE		
Examiner	Signa	ature				Date Considered	1	
						formance with MPEP 609 with next communication		

F

E

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10561880
Filing Date		2005-12-23
First Named Inventor Quian		mbao, Jr.
Art Unit		
Examiner Name		
Attorney Docket Numb	er	733310/00001A

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make t	the appropriate selection(s):
---------------	----------	--------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torn or the signature.							
	Signature	/Michael B. Pallay/	Date (YYYY-MM-DD)	2007-06-18			
	Name/Print	Michael B. Pallay	Registration Number	50 230			

This collection of information is required by 3T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.